Close

MoU Inked By The UK And Sweden To Engage In Lifesciences

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

The United Kingdom and Sweden have reached a deal through an MoU recognising their existing bilateral collaboration in the biological sciences. The goal of the MoU is to foster collaboration among participants in the health, research, as well as innovation systems at the local, regional, and federal levels in order to promote the growth of innovative, efficient, and appealing lifescience ecosystems. The participants’ cooperation shall be founded on the principles of fairness, reciprocity, and mutual benefit and all applicable laws and institutions from both nations.

Early diagnosis, genomes, and other areas of collaboration are expected to be among the first areas of cooperation, according to the attendees. Clinical studies, legislative innovation, application of advancement, production methods, life sciences sector sustainability, and antibiotic resistance are all topics that need to be addressed.

Cooperative actions to foster discussion on these themes could also include:

  • Partnership in policy, design, and execution of technical standards is required in the lifesciences sector to develop data-driven approaches.
  • Policy, strategy, and market interventions all benefit from knowledge exchange.
  • Collaboration in policy formulation to create a dynamic marketplace via business involvement and active participation.
  • Collaboration in the discovery, testing, and deployment of innovative technologies and therapies.

Furthermore, the participants applaud the existing research partnership between the United Kingdom and Sweden, which includes collaborations between corporations, institutions of higher learning, health and research organisations, and other stakeholders. They encourage scholars from both countries to collaborate more closely in the future, including through multilateral collaborations and combined submissions to European research and innovation programmes.

Latest stories

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back